Leveraging derisked AAV vector development & delivery approaches to enhance speed to market for rare disease gene therapies

Speed to clinic and to market reign supreme in today’s gene therapy biotech sector, so why reinvent the wheel?
David McCall, Senior Editor, BioInsights, speaks to (pictured) Adrien Lemoine, Co-Founder and Chief Executive Officer, Bloomsbury Genetic Therapies about the efficiencies and derisking benefits to be derived from building on established know-how and regulatory precedents in the AAV-driven gene therapy space.

Please enter your email to access content Read now